Targeting peroxiredoxin 2 prevents hepatocarcinogenesis in metabolic liver disease. Crouchet E, Schaeffer E, Oudot MA, et al. Targeting peroxiredoxin 2 prevents hepatocarcinogenesis in metabolic liver disease. The Journal of clinical investigation. 2025. doi:10.1172/JCI169395 Read more